Skip to content

PTC Therapeutics PTCT Increase (Decrease) in Prepaid Expense and Other Assets

Increase (Decrease) in Prepaid Expense and Other Assets at other companies

ALN
Alnylam PharmaceuticalsALNY
BridgeBio Pharma logo
BridgeBio PharmaBBIO
Arrowhead Research logo
Arrowhead ResearchARWR
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
LQD
Liquidia CorporationLQDA

Other financials

Income statement

See full
Revenue$272.6M-76.8%
Operating income$45.0M-95.4%
Net income-$2.8M-100%
EPS (diluted)-$0.03-100%

Balance sheet

See full
Cash & equivalents$834.0M-43.7%
Total debt$395.1M+0.1%
Total equity-$180.5M+2.9%
Total assets$2.9B+8.0%

Cash flow

See full
Operating cash flow-$59.0M-107%
CapEx$1.2M-30.6%
Free cash flow-$60.2M-107%

Valuation

See full
Market cap$6.55B+40.3%
Enterprise value$6.11B+77.3%
P/E
P/S7.9×+5.3×

Profitability

See full
Gross margin96%
Operating margin1.6%-38.7pp
Net margin42.3%+27.4pp
FCF margin39.1%+32.8pp

Returns & leverage

See full
Return on equity-216.7%
Debt / equity372.3×
Current ratio2.4×-1.5×

Where this comes from

Reported directly by PTC Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets.

The official record: PTC Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about PTC Therapeutics's increase (decrease) in prepaid expense and other assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is PTC Therapeutics's increase (decrease) in prepaid expense and other assets?
PTC Therapeutics (PTCT) reported increase (decrease) in prepaid expense and other assets of -$1.18M in Q1 2026.
How has PTC Therapeutics's increase (decrease) in prepaid expense and other assets changed year-over-year?
PTC Therapeutics's increase (decrease) in prepaid expense and other assets decreased by 107.2% year-over-year, from $16.43M to -$1.18M.
What is the long-term trend for PTC Therapeutics's increase (decrease) in prepaid expense and other assets?
Over 3 years (2021 to 2024), PTC Therapeutics's increase (decrease) in prepaid expense and other assets has grown at a 91.8% compound annual growth rate (CAGR), from $15.31M to -$107.96M.
What does increase (decrease) in prepaid expense and other assets mean?
This tracks changes in cash paid in advance for goods or services that will be consumed in future periods. It reflects the timing difference between cash outflows and the recognition of related expenses on the income statement.